FDA Approves Brepocitinib as First Oral Drug for Dermatomyositis

The FDA approved brepocitinib as the first oral targeted therapy for adult dermatomyositis, supported by phase 3 trial data demonstrating substantial improvement in muscle, skin, and overall disease symptoms with reduced steroid dependence.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 27 Aug 2026 and 2 Sep 2026.